Immupharma PLC Result of AGM (7744K)
June 27 2014 - 8:11AM
UK Regulatory
TIDMIMM
RNS Number : 7744K
Immupharma PLC
27 June 2014
FOR IMMEDIATE RELEASE 27 JUNE 2014
ANNUAL GENERAL MEETING: 2014
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, held its AGM
earlier today and is pleased to announce that all resolutions were
duly passed. A summary of proxy votes is shown in the table below.
Please also refer to the 'Notice of Meeting' in the Report &
Accounts - 31 December 2013 (page 56).
RESOLUTION FOR % AGAINST % WITHHELD
------------- ----------- ------ ---------- ------ ---------
1* 42,555,134 97.12 1,260,750 2.88 141,750
------------- ----------- ------ ---------- ------ ---------
2 43,294,291 98.59 620,750 1.41 276,450
------------- ----------- ------ ---------- ------ ---------
3 37,577,751 85.31 6,472,290 14.69 141,450
------------- ----------- ------ ---------- ------ ---------
4 43,655,791 99.10 394,250 0.90 141,450
------------- ----------- ------ ---------- ------ ---------
5 43,402,829 98.53 645,750 1.47 142,912
------------- ----------- ------ ---------- ------ ---------
6 (Special
Resolution) 43,392,429 98.51 657,612 1.49 141,450
------------- ----------- ------ ---------- ------ ---------
*A poll was requested at the AGM and completed. The resolution
was passed. All other resolutions were passed by a show of
hands.
As part of the formal proceedings Dimitri Dimitriou Chief
Executive Officer made the following statement:
It is important to focus on the progress ImmuPharma has made
over the last financial period and the embedded value of the
assets. There have been many achievements in 2013, including the
grant by the FDA of a new and more attractive agreed protocol for
our phase III trial of Lupuzor, the appointment of a very
prestigious Scientific Advisory Board for Lupuzor with some of the
leading Lupus opinion leaders in the US and Europe and the GBP50m
facility from Darwin. Our Nucant cancer phase I/IIa trial will be
reporting results soon. In addition, we recently announced that we
have been granted new patents surrounding an "optically pure"
version of ImmuPharma's Nucant family which broadens our usage into
other indications. Furthermore, through our collaboration with the
CNRS, and announced only this morning, ImmuPharma has provided
further details on its access to pioneering research in the
Bordeaux region of France centred around novel peptide drugs
through the University of Bordeaux and the Institut Européen de
Chimie et Biologie (IECB).
Our key focus remains the progress of our lead compound Lupuzor
into Phase III and we hope to provide an update in the near
future.
The Board would like to thank its shareholders for their
continued support as well as its scientific advisors and the CNRS
for their long standing collaboration."
For further information please see the Group's web site,
www.immupharma.com, or contact:
ImmuPharma PLC +44 20 7152 4080
Richard Warr, Chairman
Dimitri Dimitriou, Chief Executive
Officer
Tracy Weimar, VP Operations
and Finance
Lisa Baderoon, Head of Investor +44 7721 413
Relations 496
Panmure Gordon +44 20 7886 2500
Hugh Morgan, Fred Walsh, Duncan
Monteith
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGGMGZVZNLGDZM
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024